Legend Biotech's stock surged 41.72% over five trading days, a significant rally for a stock that had declined for over six months with a peak-to-trough drop exceeding 60%. This upward movement was fueled by both strong financial results and shifting market sentiment.
On April 14, Johnson & Johnson released its Q1 2026 financial report. The company's total revenue for the quarter reached $24.1 billion, with oncology drug revenue contributing $6.973 billion. Legend Biotech's Carvykti, developed in partnership with Johnson & Johnson, was a key growth driver within this segment, achieving sales of $597 million for the quarter, a year-over-year increase of 62.1%. This robust performance led markets to anticipate the drug's annual sales will surpass $2.5 billion this year, potentially making it the first blockbuster therapy in the CAR-T field. This strong earnings report acted as a powerful catalyst, driving Legend Biotech's stock price up 5.65% on April 14 and 9.79% on April 15.
However, the primary catalyst for the sharp price appreciation appears to be market sentiment sparked by Eli Lilly's announcement on April 20 of an acquisition of Kelonia for a total potential consideration of up to $7 billion. This news seems to have been the key driver behind the stock's major rally.
A $7 Billion Acquisition Prompts Market Reassessment A series of major acquisitions have targeted the in vivo CAR-T space over the past year. This includes AstraZeneca's $1 billion acquisition of EsoBiotec in March last year, AbbVie's $2.1 billion acquisition of Capstan Therapeutics and Gilead's $350 million acquisition of Interius BioTherapeutics in August, and Bristol Myers Squibb's $1.5 billion acquisition of Orbital Therapeutics in October. Lilly's deal for Kelonia, involving a $3.25 billion upfront payment and a total potential value of $7 billion, has escalated this multinational corporation "shopping spree" to a new level.
The market's strong reaction is due not only to the substantial $7 billion price tag but also to the fact that Kelonia's core CAR-T therapy, KLN-1010, is supported by early data from just four patients with three months of follow-up. Essentially, Lilly's significant investment is not solely for this specific therapy but for the company's core technology—the iGPS platform, an in vivo CAR-T platform based on a modified lentiviral vector. This platform is theoretically capable of accommodating any CAR configuration, targeting any antigen, and covering any indication.
Data presented at last year's ASH annual meeting for KLN-1010 showed that all four initial patients achieved MRD negativity, resulting in a 100% response rate. The therapy also demonstrated a favorable safety profile with no severe cytokine release syndrome and did not require lymphodepleting pretreatment. The deal indicates that Lilly is betting primarily on Kelonia's in vivo CAR-T platform, focusing on overcoming the key bottlenecks of traditional CAR-T therapies related to manufacturing, cost, and time. This is the core promise of "off-the-shelf" CAR-T technologies.
However, this technology has not yet supplanted traditional ex vivo CAR-T because many candidates still face significant challenges in delivery efficiency, safety control, and durability of response. For example, Caribou Biosciences reported positive Phase 1 trial data for its off-the-shelf CAR-T therapy CB-010 in May 2022, showing a 100% ORR and 80% CR in evaluable patients. Yet, less than a month later, the company announced a cancer relapse within six months post-treatment for a patient, raising serious doubts about the therapy's durability and causing its stock to plummet over 20%.
Therefore, the primary limitation for Kelonia's KLN-1010 is the current lack of long-term data, supported by only three months of follow-up from four patients. Lilly's $7 billion bet is placed on a technology platform and product yet to be validated by long-term data and commercial performance, prompting deep reflection among market investors.
The Sharp Rally May Just Be the Beginning Currently, the lead indication for Kelonia's KLN-1010 is multiple myeloma, placing it in the same therapeutic area as Legend Biotech's Carvykti. It is important to note that Carvykti is the first and only BCMA CAR-T therapy approved for second-line treatment of multiple myeloma and is expected to move earlier in the treatment pathway, potentially becoming a cornerstone therapy. The therapy generated nearly $600 million in sales in Q1 and, with projected annual sales of $1.887 billion by 2025, is on track to become the world's best-selling CAR-T therapy. This performance is expected to lead Legend Biotech to operational profitability this year.
Against this backdrop, Legend Biotech's market capitalization stood at just $3.916 billion as of April 17, only about $700 million higher than the upfront payment Lilly is making for Kelonia and significantly below the deal's total potential value of $7 billion. This suggests that Legend Biotech is severely undervalued at its current market price.
Fundamentally, according to Legend Biotech's disclosed financials, top-line data from the CARTITUDE-5 trial for Carvykti is expected within the next year or two. This trial prospectively includes MRD activity testing, potentially positioning Legend as the first company to discuss the correlation between MRD negativity and progression-free survival/overall survival in CAR-T therapy with the FDA, ultimately advancing Carvykti into first-line treatment. Beyond Carvykti, Legend's own in vivo CAR-T project, LVIVO-TaVec100, initiated a Phase I IIT clinical trial in May last year and has completed its first patient dosing, with preliminary data expected in the second half of this year.
From a short-term technical perspective, the nearly 40% surge over five days, driven by earnings and market news, was accompanied by rising trading volume. Daily volume exceeded 3 million shares on April 16 and reached 7.4065 million shares on April 20, indicating a pattern of rising price with rising volume. However, this rapid ascent has triggered clear overbought signals. Technical indicators on April 20 showed that while the MACD histogram supported an upward trend following a golden cross, the RSI reached 91.88, indicating severe overbought conditions. Simultaneously, the KDJ indicator was at a high level of 76.51, and the price broke above the upper Bollinger Band, suggesting significant short-term pullback pressure.
From a medium-to-long-term perspective, after a decline lasting over six months, Legend Biotech's stock began consolidating at low levels from February this year. Daily trading volume decreased noticeably as selling pressure diminished. With major investors accumulating positions, a clear single-peak formation has appeared on the筹码分布图 after sufficient turnover, indicating strong accumulation and a high degree of control by major holders. The recent high-volume breakout above this single-peak consolidation zone further confirms the pattern, presenting a technical signal for medium-to-long-term entry.
Comments